BioCentury
ARTICLE | Tools & Techniques

Calibrating PD-L1

How Flagship hopes to obviate the need to run different PD-L1 assays for every drug

March 17, 2017 10:07 PM UTC

Flagship Biosciences Inc.’s Computational Tissue Analysis platform won’t provide a common cutoff point across the five major assays used to measure PD-L1 expression. But it could calibrate the output so that results from one assay can be used to predict the scores the other assays would produce for the same sample.

That would allow oncologists to make decisions about using any marketed PD-1 or PD-L1 therapy without necessarily having to order the corresponding assay...